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Abstract
Background: A higher increase in intracellular Na
+ via Na
+/H
+ exchanger (NHE) during ischemia has been reported
in type 2 diabetic mouse hearts. We investigated the role of NHE in inducing changes in cytoplasmic Ca
2+
concentration ([Ca
2+]i) and alterations in ventricular function during ischemia-reperfusion in type 2 diabetic mouse
hearts.
Methods: Hearts from male type 2 diabetic db/db (12-15 weeks old) and age-matched control db/+ mice were
subjected to Langendorff perfusion and loaded with 4μM of the Ca
2+ indicator fura-2. The hearts were exposed to
no-flow ischemia for 15 minutes and then reperfused. [Ca
2+]i was measured by monitoring fura-2 fluorescence at
500 nm (excitation wavelengths of 340 and 380 nm), while left ventricular (LV) pressure was simultaneously
measured.
Results: db/db hearts exhibited a lower recovery of LV developed pressure than db/+ hearts during reperfusion
following ischemia. Diastolic [Ca
2+]i was increased to a greater level in diabetic hearts than in the control hearts
during ischemia and reperfusion. Such an increase in cytoplasmic Ca
2+ overload during ischemia-reperfusion in
diabetic hearts was markedly reduced in the presence of the NHE inhibitor cariporide. This was accompanied by a
significantly improved recovery of ventricular function on reperfusion, as shown by a lower increase in diastolic
pressure and increased recovery of developed pressure.
Conclusion: NHE plays a key role in enhancing cytoplasmic Ca
2+ overload during ischemia-reperfusion and
severely impairing post-ischemic cardiac function in hearts from type 2 diabetic db/db mice.
Background
Diabetes mellitus (DM) has been reported to be an inde-
pendent predictor of cardiovascular morbidity and mor-
tality in patients with ischemic heart disease [1], as well
as heart failure [2], while direct deleterious effects of DM
on hearts also have been reported [3]. However, few
investigations of the cardiac consequences of type 2 dia-
betes, particularly in regard to sensitivity to ischemia,
have been performed [4-6]. It is recognized that cytoplas-
mic Ca
2+ overload is an important mechanism in myo-
cardial ischemic injury [7-10]. Cytoplasmic Ca
2+ overload
occurs via a combination of activities of Na
+/H
+
exchanger (NHE) and Na
+/Ca
2+ exchanger (NCX), with
the latter functioning in the reverse mode [9-13].
Changes in cytoplasmic Ca
2+ concentration ([Ca
2+]i) dur-
ing ischemia have not been evaluated in type 2 diabetic
hearts. We previously reported that a highly increased
intracellular Na
+ concentration ([Na
+]i), mainly via NHE,
caused enhanced sensitivity to ischemia in type 2 diabetic
db/db mouse hearts [5]. Therefore, we speculated that
NHE plays a key role in cytoplasmic Ca
2+ overload in
ischemic cardiomyocytes of type 2 diabetic hearts.
The purpose of the present study was to determine
changes in diastolic [Ca
2+]i and Ca
2+ transient amplitude
during ischemia and reperfusion in isolated type 2 dia-
betic db/db mouse hearts loaded with fura-2, a fluores-
cent dye [8,14]. The correlation between [Ca
2+]i and
cardiac function was investigated, as well as the impor-
tance and role of NHE in [Ca
2+]i changes.
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Experimental animals
This study was conducted in accordance with the guide-
lines of the Guidance Committee of the Jikei University
School of Medicine for the Use and Care of Animals,
and conformed to the Guidelines for the Care and Use
of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996). Male BKS. Cg- + Lepr
db/+Lepr
db/Jcl (db/db) mice
and their non-diabetic heterozygous control littermates
BKS. Cg-m+/+Lepr
db/Jcl (db/+)m i c ew e r ep u r c h a s e d
from CLEA Japan (Tokyo, Japan). All animals used in
this study were males between 12 and 15 weeks of age.
The animals were housed in groups (4 or 5) and given
free access to food and water.
Isolated perfused heart preparation
Mice were anesthetized with sodium pentobarbital
(100 mg/kg) and heparinized (100U) i.p. Each heart was
then quickly removed and the ascending aorta was cannu-
lated with a 19-gauge steel cannula. Langendorff’sr e t r o -
grade perfusion (80 mmHg perfusion pressure) was started
with N-2-hydroxy-ethylpiperazine-N’-2-ethansulfonic acid
(HEPES)-buffered Tyrode’s solution (140 mM NaCl, 6 mM
KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 10 mM
glucose, gassed with 100% O2, pH 7.4, 37°C). Hearts were
not perfused in the presence of fatty acids [15,16]. All per-
fusion solutions were filtered prior to use. Isovolumic left
ventricular developed pressure (LVDP), heart rate, and
maximum and minimum first derivatives of developed
pressure (dP/dt max and dP/dt min) were monitored using
a fluid-filled polyvinylchloride film balloon inserted into
the left ventricle via the mitral valve. The balloon was con-
nected to a Statham 23 ID pressure transducer and poly-
graph system (Nihon Koden Co., Japan). The initial left
ventricular end diastolic pressure (LVEDP) was adjusted to
0 mmHg. LVDP was calculated by subtracting LVEDP
from systolic pressure. Pressure signals were obtained
using a PowerLab data acquisition system (AD Instruments
Japan, Tokyo, Japan). The hearts were allowed to contract
spontaneously in all the experiments.
Fluorescence measurements
Intracellular Ca
2+ levels were measured by the use of the
cell-permeable Ca
2+ sensitive fluorescent dye, fura-2/acet-
oxymethyl ester (AM) (Dojindo Laboratories, Japan), with
an optical-fiber analysis system (CAF-110, CA-200DO;
Japan Spectroscopic Co., Japan) [8,9]. Following 30 min-
utes of stabilization, the heart was loaded for 30 minutes
by simple perfusion in constant flow system that main-
tained a coronary flow rate of ≃ 2.2-2.5 ml/minute with a
peristaltic pump. The loading buffer (Tyrode’ss o l u t i o n )
contained 4 μM of fura-2/AM and was given for 30 min-
utes. During the subsequent 20 minutes, the heart was
perfused with normal Tyrode’ss o l u t i o nt ow a s ho u tt h e
dye in the extracellular space. The fluorescent dye was dis-
solved in dimethyl sulfoxide containing Cremophor EL
(25% w/v). Excitation light from a Xe lamp was transferred
via the fiber onto the epicardial surface of the LV and the
fluorescent light was collected through another fiber onto
a photomultiplier. The ratio of 500 nm fluorescence inten-
sity (F340 /F380) excited at 340 and 380 nm of UV light was
monitored as a quantitative index of [Ca
2+]i,a n dw a si n d e -
pendent of the fura-2 concentration. Background auto-
fluorescence was subtracted to assess diastolic [Ca
2+]i.W e
evaluated changes in diastolic [Ca
2+]i by using the follow-
ing equation to equalize the differences in fura-2 loading









Where, R is the diastolic ratio, Rpre is the pre-ischemic
diastolic ratio and Apre is the amplitude of pre-ischemic
ratio. Each ratio was calculated from the value of fluores-
cence intensity at 340 nm (autofluorescence subtracted)
divided by fluorescence intensity at 380 nm (autofluores-
cence subtracted). Each ratio was expressed in arbitrary
units. Calibration of fura-2 was not performed. Through-
out the experiment, we simultaneously monitored fura-2
fluorescence and hemodynamic parameters.
Experimental protocol
Based on results from pilot experiments, the experimen-
tal protocol consisted of 10 minutes of control perfu-
sion, followed by 15 minutes of no-flow ischemia and
15 minutes of reperfusion. In each group, diabetic and
non-diabetic hearts either received or did not receive
the NHE inhibitor cariporide (1 μmol/l; a gift from
Aventis Pharma) [5,11,13,17,18]. When present, caripor-
ide was added to the perfusion solution at 10 minutes
before inducing ischemia and remained throughout.
Analysis of plasma metabolites
Blood samples (fed dietary status) were taken from the
body cavity after excision of the heart. Plasma glucose
was measured using a glucose oxidase method.
Statistical analysis
Results are presented as the means ± SEM. The data
were analyzed using either Student’stt e s tf o ru n p a i r e d
data or ANOVA, followed by the appropriate post hoc
test, using Scheffe’s test to locate differences between
groups. Significance was set at p < 0.05.
Results
Animal characteristics
At 12-15 weeks of age, body weights and plasma glucose
levels in diabetic db/db mice were significantly higher
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These observations are in agreement with those of pre-
vious studies [4,5,17,19].
Pilot experiments
In pilot experiments without the ischemia-reperfusion
protocol, a decrease of LVDP by 12% was observed after
fura-2 loading and the washing out process. Bleaching
of fura-2 was observed after 60 minutes of perfusion.
Fluorescence intensities and ratios were stable, and did
not decrease during at least 50 minutes of perfusion.
When the initial LVEDP was adjusted to 10 mmHg,
LVDP tended to decrease after 50 minutes of perfusion
in both db/db and db/+ hearts. However, when that was
adjusted to 0 mmHg, a stable LVDP time course was
observed during the 50 minutes of perfusion.
Several durations of ischemia were assessed after fura-
2 loading and the washing out process. Following only
10 minutes of ischemia cardiac function recovered well
in both diabetic and control groups, whereas poor func-
tion recovery was observed after ischemic periods longer
than 20 minutes. All of the following experiments were
therefore performed with ischemia duration of 15
minutes.
Ventricular function and [Ca
2+]i during control perfusion
in hearts from diabetic db/db mice
Original trace recordings of fura-2 fluorescence, ratios
and LVP during control perfusion are illustrated in
Figure 1. Autofluorescence was not subtracted. Ca
2+
recordings revealed phasic changes with steep upstrokes
and slow declines.
Systolic and diastolic levels of the F340/F380 ratio were
stable, indicating that heart movements did not affect
these levels. LVDP measured after 30 minutes of perfu-
sion was in the range of values previously reported [5] for
mouse hearts under similar conditions, with no differ-
ence between control and diabetic hearts that received or
not cariporide (Table 2). Likewise, cariporide did not
influence heart rate or calcium measurements in both
db/db and db/+ mouse hearts. Also, diastolic fura-2
fluorescence ratio and Ca
2+ transient amplitude showed
similar levels in both groups (Table 2). However, the
duration of Ca
2+ transients was increased in diabetic db/
db hearts compared with that in non-diabetic db/+
hearts, as revealed by time-to-peak transient values and
duration at 50% recovery. Differences in Ca
2+ transients
between diabetic and non-diabetic hearts remain
unchanged in the presence of the NHE inhibitor caripor-
ide. Such an observation is consistent with previous
observations of altered calcium handling in ventricular
myocytes from diabetic animals resulting primarily from
dysfunction of the sarcoplasmic reticulum [20].
Ventricular function during ischemia and after
reperfusion in hearts from diabetic db/db mice
After inducing ischemia, LVDP decreased to 0 over 1-2
minutes in hearts from both diabetic db/db and db/+
mice, and LVEDP increased (Figures 2, 3, 4). At the end of
ischemia, LVEDP in diabetic db/db hearts was significantly
higher (41.3 ± 3.1 mmHg) compared with that in control
db/+ hearts (31.4 ± 2.8 mmHg, p < 0.05, Figure 3). Car-
iporide did not significantly affect the rise in LVEDP in
db/+ hearts during ischemia and reperfusion (Figure 3),
whereas it significantly reduced it in db/db hearts at the
end of ischemia (Figure 3). Figure 4 shows the recovery
rate of LVDP, which was significantly lower in db/db
hearts compared with that in db/+ hearts throughout
reperfusion (42.5 ± 3.8% and 81.2 ± 3.0%, respectively, at
15 minutes of reperfusion, p < 0.01). Cariporide improved
the recovery of LVDP in both groups of hearts (Figure 4).
However, the positive effect of cariporide was clearly sig-
nificant only in hearts from diabetic db/db mice (80.5 ±
5.2% in the presence of cariporide vs. 42.5 ± 3.8% in its
absence, Figure 4). In the present study we did not record
electrocardiogram, which we had done previously [5], thus
the influence of arrhythmia is unclear.
Changes in [Ca
2+]i during ischemia and after reperfusion
in hearts from diabetic db/db mice
Figure 2 illustrates typical original traces obtained from
individual hearts throughout the experiment. Back-
ground autofluorescence was not subtracted in any trace
showing fura-2 ratio. In hearts from both non-diabetic
db/+ (Figure 2A) and diabetic db/db (Figure 2B) mice,
diastolic ratio levels elevated gradually during ischemia
and additional elevations were observed immediately
upon reperfusion. These ratios tended to return to pre-
ischemic values during reperfusion. The amplitude of
Ca
2+ transients rapidly decreased during ischemia in
both heart groups. A progressive increase was observed
during reperfusion.
We also investigated the effects of ischemia and
reperfusion on myocardial autofluorescence. It has
been demonstrated that the majority of autofluores-
cence is due to the intracellular metabolite NAPDH
[21]. Figure 5 shows original traces of fluorescence
changes at 340 and 380 nm, as well as their ratio, from
unloaded hearts of both db/+ and db/db mice. The
Table 1 Characteristics of control (db/+) and diabetic
(db/db) mice
db/+ db/db
(n = 17) (n = 17)
Body weight (g) 29.4 ± 0.5 51.0 ± 1.0 *
Plasma glucose (mg/dl) 226.1 ± 8.0 615.6 ± 10.1**
Values are the means ± SE. * p < 0.05, ** p < 0.01 vs. db/+ mice
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ing ischemia and then decreased to the baseline value
after reperfusion. It should be noted that fluorescence
excited at 340 or 380 nm did not change significantly
throughout the experiment. In the unloaded hearts, the
ischemia-induced alteration of each fluorescence inten-
sity (n = 4) was smaller compared with the loaded
hearts. However, the increase in autofluorescence at
340 nm was larger than that at 380 nm after induction
of ischemia, though the value for each remained con-
stant during ischemia. The average values (arbitrary
units) from 4 hearts in each groups were as follow: (i)
0.12 and 0.20, at 340 and 380 nm, respectively, during
control perfusion and reperfusion, (ii) 0.16 and 0.21, at
340 and 380 nm, respectively, during ischemia. There-
fore, the change in diastolic level of fluorescence ratio
might have been overestimated during the early phase
of ischemia when autofluorescence was not subtracted.
It has been previously found that autofluorescence at
both 340 and 380 nm increased in parallel during
ischemia, with the result that the ratio remained con-
stant [22]. In the present study, all hearts showed a
large amplitude of fluorescence ratios, which likely lim-
ited any effect of changes in autofluorescence.
Figure 1 Original traces showing F340 and F380, F340/F380 ratio and left ventricular pressure in hearts from control db/+ (A) and
diabetic db/db (B) mice. Ca-T amp, Ca
2+ transient amplitude; Diast ratio, diastolic fura-2 ratio; LVP, left ventricular pressure. *Autofluorescence
not subtracted.






(n = 9) (n = 9) (n = 8) (n = 8)
LVDP (mmHg) 103.9 ± 4.9 103.5 ± 8.5 104.2 ± 5.6 102.4 ± 7.8
Heart rate (bpm) 370.3 ± 16.2 309.6 ± 25.0* 358.6 ± 16.8 307.9 ± 18.9
dP/dt max (mmHg/ms) 3.70 ± 0.20 2.98 ± 0.33 3.71 ± 0.30 2.96 ± 0.20
dP/dt min (mmHg/ms) 3.04 ± 0.14 2.35 ± 0.21* 3.06 ± 0.25 2.34 ± 0.18
Diast ratio (a.u.) 1.31 ± 0.04 1.37 ± 0.02 1.32 ± 0.08 1.38 ± 0.05
Ca-T amp (a.u.) 0.60 ± 0.04 0.51 ± 0.03 0.59 ± 0.06 0.50 ± 0.07
TTP (ms) 37.5 ± 1.4 45.8 ± 5.1* 38.8 ± 1.3 45.6 ± 3.3
DT50 (ms) 62.1 ± 2.0 81.1 ± 4.7* 63.0 ± 1.4 82.3 ± 4.2
DT100 (ms) 128.1 ± 4.3 150.1 ± 14.6 130.4 ± 4.1 149.8 ± 11.5
Values are the means ± SE. LVDP, left ventricular developed pressure; dP/dt max and dP/dt min, maximum and minimum first derivatives of developed pressure;
Diast ratio, diastolic fura-2 fluorescence ratio; Ca-T amp, amplitude of Ca
2+ transient; a.u., arbitrary unit; TTP, time-to-peak Ca
2+ transient; DT50, 50% decay-time of
Ca
2+ transient, DT100, 100% decay-time of Ca
2+ transient. Background autofluorescence was subtracted for fura-2 fluorescence study. * p < 0.05 vs db/+ mice
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ischemia and reperfusion. Diastolic fura-2 ratio increased
more rapidly during no-flow ischemia in hearts from dia-
betic db/db mice than in those from control non-diabetic
db/+ mice, reaching 56.0 ± 7.2% and 15.0 ± 2.6%,
respectively, of the control values (p < 0.01) at the end of
ischemia. Throughout reperfusion, diastolic fura-2 ratios
remained elevated in hearts from diabetic db/db mice and
were significantly higher than those in hearts from non-
diabetic db/+ mice. Cariporide treatment markedly
Figure 2 Original traces showing F340/F380 ratio and left ventricular pressure during ischemia and reperfusion in hearts from db/+
(A) and db/db (B) mice.
Figure 3 Changes in left ventricular end-diastolic pressure during ischemia and reperfusion in hearts from non-diabetic db/+ mice
(closed circles, n = 9), diabetic db/db mice (closed triangles, n = 9), non-diabetic db/+ mice that received cariporide (open circles, n =
8), and diabetic db/db mice that received cariporide (open triangles, n = 8).* p < 0.05 vs. db/+,
†p < 0.05 vs. without cariporide.
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from diabetic db/db mice, during both ischemia and
reperfusion.
Discussion
The main finding obtained in the present study was a
marked decrease in cytoplasmic Ca
2+ overload during
ischemia-reperfusion in hearts from diabetic db/db mice
in the presence of the NHE inhibitor cariporide. This
was accompanied by significantly improved recovery of
ventricular function on reperfusion, as assessed from
our findings of a lower increase in diastolic pressure and
increased recovery of developed pressure.
In agreement with previous reports that used mice
under similar experimental conditions (i.e., same age
and similar control perfusion conditions) [4-6], we
found no difference in ventricular function between
control and diabetic hearts (Table 2). Basal alterations
Figure 4 Percent changes in left ventricular developed pressure during ischemia and reperfusion in hearts from non-diabetic db/+
mice (closed circles, n = 9), diabetic db/db mice (closed triangles, n = 9), non-diabetic db/+ mice that received cariporide (open
circles, n = 8), and diabetic db/db mice that received cariporide (open triangles, n = 8).* p < 0.05 vs. db/+,* * p < 0.01 vs. db/+,
†p < 0.05
vs. without cariporide,
††p < 0.01 vs. without cariporide.
Figure 5 Original traces showing F340 and F380, F340/F380 ratio and left ventricular pressure in hearts from fura-2 unloaded db/+ (A)
and db/db (B) mice.
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2+]i in hearts from diabetic db/db mice have been
reported by several investigators. Belke et al. noted
increased Ca
2+ leakage from the sarcoplasmic reticulum
(SR) [19], while impaired [Ca
2+]i cycling due to reduc-
tions in expressions of both sarcolemmal Ca
2+ channels
and SR Ca
2+ release channels were demonstrated by
Pereira et al. [23]. In the present study, during the con-
trol perfusion period, time to peak and decay time of
Ca
2+ transient were significantly prolonged in db/db
hearts (Figure 1 and Table 2). Our observations are in
agreement with the above reports and represent a con-
sistent feature of ventricular myocytes in diabetic hearts
[20]. It has been shown that increased saturated fatty
acid levels impair Ca
2+ handling and contraction in a
reactive oxygen species (ROS)-dependent manner in
normal cardiomyocytes [15]. However, it remains to be
determined whether increased fatty acid utilization
interferes with Ca
2+ handling in diabetic db/db mouse
hearts. Basal alterations in [Ca
2+]i might precipitate
cytoplasmic Ca
2+ overload during ischemia-reperfusion,
as we observed in the present db/db hearts. On the
other hand, cytoplasmic Ca
2+ overload in these hearts
was largely prevented by the presence of the NHE inhi-
bitor cariporide (Figure 6). This finding indicates a
major role for the ionic exchanger NHE in Ca
2+ over-
load. It is known that increases in [Na
+]i in ischemic
cardiomyocytes [5] generate Ca
2+ loading via reverse
Na
+/Ca
2+ exchanger, which in turn mediates much of
the damage incurred upon reperfusion [24]. In this con-
text azelnidipine [25] and ranolazine [26] have also been
shown to be efficient at reducing intracellular calcium
accumulation.
NHE is a key element in the physiological response of
[Ca
2+]i and Ca
2+ signaling in cardiomyocytes [27-29], and
its activation has been reported to be correlated with car-
diac hypertrophy via this system [17,27,29]. The present
results are in line with our previous report that showed
higher [Na
+]i increase during ischemia and severely
impaired post-ischemic cardiac function in hearts from
diabetic db/db mice. In that study, NHE inhibitor car-
iporide reduced ischemia-induced [Na
+]i increase and
improved post-ischemic cardiac function in db/db hearts
[5]. Likewise, elevation of diastolic fura-2 ratio in the pre-
sent study was attenuated during ischemia and reperfu-
sion and functional alterations on reperfusion were
markedly reduced by cariporide in diabetic db/db hearts.
Taken together, our previous [5] and present results sug-
gest that the role of NHE is more important for ische-
mia-induced cytoplasmic Ca
2+ overload and myocardial
damage in diabetic db/db hearts than in control db/+
hearts. Moreover, enhanced NHE activity during ische-
mia in db/db hearts can be inferred from these results.
Indeed, enhanced NHE activity in ventricular myocytes
has been reported in another genetic model of type 2
Figure 6 Changes in diastolic fura-2 ratio during ischemia and reperfusion in hearts from non-diabetic db/+ mice (closed circles, n =
9), diabetic db/db mice (closed triangles, n = 9), non-diabetic db/+ mice that received cariporide (open circles, n = 8), and diabetic
db/db mice that received cariporide (open triangles, n = 8).* p < 0.05 vs. db/+, **p < 0.01 vs. db/+,
†p < 0.05 vs. without cariporide,
††p <
0.01 vs. without cariporide.
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of HCO3
- free, HEPES buffered perfusion solution might
have enhanced the contribution of NHE1 in the present
study [30]. Among known factors stimulating cardiac
NHE1 activity are [Ca
2+]i [31,32] and angiotensin II
[33-35]. In ventricular myocytes of diabetic db/db mice,
NHE1 activity might be stimulated by basal alterations in
[Ca
2+]i,d u et oi n c r e a s e dC a
2+ leakage [18]. Future work
will have to examine NHE1 activity in cardiac myocytes
of diabetic db/db mice.
Inhibition of an NHE isoform located in the mitochon-
drial membrane and reduction of mitochondrial Ca
2+
([Ca
2+]m) overload by one of the NHE blockers during
ischemia-reperfusion have been reported [36]. We cannot
exclude the possibility that cariporide may have exerted
some effects on mitochondrial NHE and [Ca
2+]m in the
present study. In addition, though these effects of car-
iporide might be different between diabetic and non-dia-
betic hearts, [Ca
2+]m cannot be selectively measured with
the methods employed in this study. Finally, NHE inhibi-
tors have recently been shown to affect mitochondria by
blunting MPTP formation and ROS release [37]. An
overproduction of mitochondrial ROS has indeed been
shown in the heart in obesity related diabetes [38].
Further studies are still needed to investigate the role of
ROS formation in ischemia-induced calcium overload in
hearts of diabetic db/db mice.
Concerning clinical applications, blockade of NHE
may provide salutary effects for diabetic patients with
ischemic heart disease through an interaction with PKB/
Akt [39,40] and other mechanisms [29,31-35]. However,
it is unfortunate that the majority of trials conducted to
test the effects of NHE inhibitors in ischemic heart dis-
ease cases have failed [41]. Intrinsically, valuable actions
of NHE might be inhibited excessively in those trials.
Hence, the methods or timings to inhibit NHE activity
should be studied. For example, partial inhibition of
aldosterone-induced genomic synthesis of NHE by
eplerenone [42] may be an important choice.
Conclusion
Cytosolic Ca
2+ overload during ischemia was much
greater in hearts from type 2 diabetic db/db mice than
in those from non-diabetic mice, which was accompa-
nied by more severe post-ischemic ventricular dysfunc-
tion. Such marked effects of ischemia in diabetic hearts
vanished in the presence of NHE inhibition. This study
highlights an important role of NHE for Ca
2+ handling
disturbances and resulting cardiac damage, particularly
in diabetic hearts.
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